Global pharma company AstraZeneca said June 27 that its cancer drugs Lynparza, developed with Merck & Co and Enhertu, developed with Japan’s Daiichi Sankyo, were recommended for the treatment of some high-risk breast cancers in the European Union. AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens, AstraZeneca sad in a release. Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast03 Phase III trial, which were published in The New England Journal of Medicine. 1 In the trial, Enhertu reduced the risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1) (hazard ratio [HR] 0. 28; 95% confidence interval [CI]: 0.
22-0. 37; p<0. 0001) in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane.
In Europe, more than 530,000 cases of breast cancer are diagnosed annually. 2 Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “This recommendation reflects the transformative progression-free survival benefit seen in the DESTINY-Breast03 trial compared to T-DM1, supporting Enhertu as a potential new standard of care and setting a new benchmark in the treatment of HER2-positive metastatic breast cancer. If approved by the European Commission, patients in Europe may be able to benefit from this important medicine earlier in the treatment of their disease, improving their chance for better outcomes.
” Gilles Gallant, Senior Vice President, Global Head, Oncology Development, Oncology R&D, Daiichi Sankyo, said: “Today’s CHMP opinion provides further validation of the significance of the DESTINY-Breast03 trial results, which for the first time showed superiority of Enhertu in prolonging progression-free survival in patients previously treated for HER2-positive metastatic breast cancer as compared to another HER2-directed ADC. This positive CHMP opinion is an important step forward in bringing this potentially practice-changing medicine to patients in Europe to use earlier in the treatment of HER2-positive metastatic breast cancer and builds on the recent approval of Enhertu in the US. ” MORE FROM THIS SECTION See All Premium Premium Indian researchers develop N95 mask with nanoparticle c .
. . Premium Premium Indian scientists studying long-term memory of covid-19 .
. . Premium Premium Scientists discover world’s largest bacterium that can .
. . Premium Premium Zika is creeping up, this time in more states The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorisations for medicines in the EU.
TRENDING STORIES See All Premium ₹54 to ₹579: Multibagger stock of 2022 surges 958% in . . .
Premium This multibagger stock fixes record date for special in . . .
Premium ‘Assault on truth’: Tharoor on Alt news co-founder’s ar . . .
Premium Horoscope Today: Money astrological predictions for Jun . . .
Subscribe to Mint Newsletters * Enter a valid email * Thank you for subscribing to our newsletter. First article Close.
From: livemint
URL: https://www.livemint.com/science/news/for-treatment-of-some-breast-cancers-2-astrazeneca-drugs-approved-by-european-union-11656316100522.html
